メインコンテンツにスキップ

Certara Announces Transition Plan For Chief Financial Officer

PRINCETON, N.J. – 2023年3月1日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective 2023年4月1日.  Mr. Schemick will transition into a newly created position as Senior Vice President, Corporate Operations and Integration, and he will be focused on supporting John’s transition, and … Continued

Certara to Participate in the Barclays Global Healthcare Conference

2023年2月27日ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healthcare Conference. Company management will present at 11:15AM ET on Wednesday, March 15th, 2023. A live webcast of the event will be available on Certara’s investor relations website at … Continued

サターラの第4四半期および通年の2022決算報告(3月1日、2023)

PRINCETON, N.J.— 2023年2月1日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. … Continued

サターラ、科学的なイノベーションを加速させる予測を実現する人工知能企業であるVyasaを買収

Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— 2023年1月4日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence (AI) capabilities to its end-to-end platform. “We are pleased to … Continued

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity PRINCETON, N.J.— 2022年12月8日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare companies, closed its previously announced $449 million new investment in Certara. … Continued

サターラ が2022年第3四半期決算を報告

Biosimulation software and services fuel third quarter growth PRINCETON, N.J.— 2022年11月7日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance. Third Quarter Highlights: Revenue was $84.7 million, compared to $73.9 million in the third … Continued

Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares PRINCETON, N.J.— 2022年11月7日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare … Continued

Certara to Participate in Upcoming Investor Conferences

2022年11月2日ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Jeffries London Healthcare ConferenceDate and Time: Tuesday, November 15 at 4:25PM GMT Stephens Annual Investment ConferenceDate and Time: Thursday, November 17 at 9:00AM CT Live webcasts for each … Continued

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions

The PMDA enters 9th consecutive year of using Certara’s software PRINCETON, N.J., 2022年10月19日 — Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ Simulator, Phoenix™ biosimulation software, and Pinnacle 21™ Enterprise software.  “The adoption of biosimulation … Continued

Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

PRINCETON, N.J.— 2022年10月13日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in … Continued

3 of 33
Powered by Translations.com GlobalLink OneLink Software